Frontlight ResearchEarly access
WithdrawnNo phase
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Sept 2022
- Ended
- 31 Aug 2025
- Type of study
- Interventional
- Treatments tested
- Islet implantation
- Record updated
- 3 September 2025
- Why it stopped
- Unable to recruit
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- T1D participants that fulfill criteria for islet transplantation
- Systemic immunosuppression
- At least one eye with VA from HM to 0.1, and fellow eye with equal or better VA
- Age ≥ 18 years
- Normal cornea with good visualization of the anterior segment
- Participant not eligible or with no wish for standard pancreatic islet into the hepatic portal system or pancreas transplantation
- Participants who have recently been involved in research or who are actively involved in research may be recruited at the discretion of the chief investigator if the active research has no impact on glucose self-management
Who cannot take part
- Ongoing treatment with intraocular anti-VEGF or steroids (and no injection within 4 weeks) in the study eye and no anticipated need for therapy during study period
- Intraocular surgery within 3 months
- Previous or planned anterior segment surgery for glaucoma
- Signs of current infection or inflammation
- VA below HM or above 0.1
- Neovascular glaucoma
- Iris neovascularization
- Ongoing retinal laser photocoagulation
- Poor visualization of the anterior chamber
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase II prospective, interventional, open-labeled, proof-of-concept study.
Read full original descriptionShow less
2 years per participant, 2 years 6 months in total Total n=6
The primary objective is to assess the safety of human pancreatic islet transplantation into the ACE of participants with T1D.
Safety analyses will involve examination of the incidence, severity, and type of treatment emergent AEs reported, and changes in vital signs, ophthalmic status and laboratory test results from baseline (Day 0 pre-transplantation) to specified time points throughout the study.
The group in the trial
- Islet implantationTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 September 2025